Labs to run: CRP (inflammation), fasting glucose (peptides rarely affect but baseline helps), CMP for liver enzymes
Key Takeaways Cagrilintide is a long-acting amylin analogue with clinical trial doses ranging from 0.3 mg to 4.5 mg weekly, while retatrutide is a triple agonist studied at 4 mg, 8 mg, and 12 mg weekly doses No published clinical trials currently exist evaluating the cagrilintide dosage with retatrutide combination, making any combined use experimental and off-label Both peptides work through different mechanismscagrilintide activates amylin receptors while retatrutide targets GIP, GLP-1, and glucagon receptorssuggesting potential complementary effects Gastrointestinal side effects (nausea, vomiting) occur in 60-80% of participants at higher doses for both compounds, raising concerns about additive effects when combined Proper dose escalation protocols spanning 8-20 weeks are critical for tolerability and adherence in peptide-based metabolic therapies Understanding Cagrilintide: Mechanism and Dosage Fundamentals What Is Cagrilintide
Emran T, Chowdhury NI, Sarker M, Bepari AK, Hossain M, Rahman GMS, Reza HM (2021) L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction
These findings support the mechanism by which CJC-1295 could influence body composition, though the study did not directly measure changes in body fat or weight
